Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis

Oestradiol and the selective oestrogen receptor modulator (SERM) raloxifene have been shown to ameliorate collagen‐induced arthritis (CIA) in rats and in mice. One aim was to investigate if raloxifene exerts its anti‐arthritic and anti‐osteoporotic effects during the induction or effector phase of arthritis. A second aim was to analyse if raloxifene activates the oestrogen response element (ERE) to produce its immune‐modulator effects. CIA or collagen–antibody‐induced arthritis (CAIA) was induced in ovariectomized DBA/1‐mice. CIA was used for evaluation of treatment during the induction, and CAIA for the effector phase of arthritis and osteoporosis development. Raloxifene, oestradiol or vehicle was administered 5 days/week. The clinical disease was evaluated continuously. Bone marrow density (BMD) was analysed with peripheral quantitative computer tomography, paws were collected for histological examination, and sera were analysed for markers of bone and cartilage turnover and proinflammatory cytokines. Transgenic luciferase (Luc)‐ERE mice were immunized with collagen (CII), and after 10 days injected once with raloxifene, oestradiol or vehicle before termination. Spleens were analysed for luciferase activity to measure ERE activation. Treatment with oestradiol or raloxifene during the induction phase of CIA failed to affect arthritis. Raloxifene did not hamper disease activity in CAIA, whereas oestradiol delayed the onset and ameliorated the severity. Both raloxifene and oestradiol preserved BMD in CAIA. CII‐immunization increased the oestradiol‐induced ERE activation in spleen, and raloxifene activated the ERE at about 25% the intensity of oestradiol. Further experiments are needed to elucidate the exact mechanisms behind this finding.

[1]  M. Cutolo Selective estrogen receptor agonism lacks clinical benefit in rheumatoid arthritis: comment on the article by van Vollenhoven et al. , 2010, Arthritis and rheumatism.

[2]  G. Herrero-Beaumont,et al.  Efficacy and safety of a selective estrogen receptor β agonist, ERB‐041, in patients with rheumatoid arthritis: A 12‐week, randomized, placebo‐controlled, phase II study , 2010, Arthritis care & research.

[3]  A. Boots,et al.  Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor α but not estrogen receptor β , 2010, Arthritis research & therapy.

[4]  B. Dijkmans,et al.  The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. , 2010, Arthritis and rheumatism.

[5]  M. Lagerquist,et al.  Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. , 2010, Arthritis and rheumatism.

[6]  M. Lagerquist,et al.  Long‐term anti‐arthritic and anti‐osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis , 2008, Clinical and experimental immunology.

[7]  Kutty Selva Nandakumar,et al.  Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. , 2008, Arthritis & Rheumatism.

[8]  M. Lagerquist,et al.  Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. , 2007, Arthritis and rheumatism.

[9]  M. Terauchi,et al.  IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation , 2007 .

[10]  M. Terauchi,et al.  IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. , 2007, The Journal of clinical investigation.

[11]  M. Stefanick Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. , 2005, The American journal of medicine.

[12]  Kutty Selva Nandakumar,et al.  Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. , 2005, Journal of immunological methods.

[13]  Don McNaughton,et al.  Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro , 2005, Arthritis research & therapy.

[14]  Kutty Selva Nandakumar,et al.  Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells. , 2005, Arthritis and rheumatism.

[15]  C. Ohlsson,et al.  Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation , 2005, Arthritis research & therapy.

[16]  M. Rowley,et al.  An arthritogenic monoclonal antibody to type II collagen, CII‐C1, impairs cartilage formation by cultured chondrocytes , 2004, Immunology and cell biology.

[17]  J. Lemmen,et al.  Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. , 2004, Journal of molecular endocrinology.

[18]  H. Offner,et al.  Estradiol Treatment Redirects the Isotype of the Autoantibody Response and Prevents the Development of Autoimmune Arthritis 1 , 2003, The Journal of Immunology.

[19]  Kutty Selva Nandakumar,et al.  Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. , 2003, The American journal of pathology.

[20]  B. Komm,et al.  Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease , 2003 .

[21]  D. Mellström,et al.  Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[22]  R. Holmdahl,et al.  Genistein as an anti-inflammatory agent , 2003, Inflammation Research.

[23]  D. Mellström,et al.  Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis , 2003, Annals of the rheumatic diseases.

[24]  B. Komm,et al.  Evaluation of an estrogen receptor-beta agonist in animal models of human disease. , 2003, Endocrinology.

[25]  C. Ohlsson,et al.  Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. , 2002, The Journal of endocrinology.

[26]  Kutty Selva Nandakumar,et al.  Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. , 2002, Arthritis and rheumatism.

[27]  S. Gabriel,et al.  Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. , 2002, Arthritis and rheumatism.

[28]  H. Hagino,et al.  Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. , 2001, Bone.

[29]  H. Carlsten,et al.  Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. , 2000, Cellular immunology.

[30]  S. Adami,et al.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. , 2000, The Journal of rheumatology.

[31]  L. Suva,et al.  The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro. , 2000, European journal of cancer.

[32]  Chisato Miyaura,et al.  Comparative Effects of Estrogen and Raloxifene on B Lymphopoiesis and Bone Loss Induced by Sex Steroid Deficiency in Mice , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  L. Joosten,et al.  Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis , 1999, Arthritis research.

[34]  J. Gustafsson,et al.  Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. , 1999, The Journal of clinical investigation.

[35]  C. Gardner,et al.  Increases in osteocalcin after ovariectomy are amplified by LPS injection: strain differences in bone remodelling. , 1998, General pharmacology.

[36]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[37]  A. Glasebrook,et al.  Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. , 1997, Science.

[38]  A. Glasebrook,et al.  Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.

[39]  B. Månsson,et al.  Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. , 1995, The Journal of clinical investigation.

[40]  D. Heinegård,et al.  Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. , 1992, British journal of rheumatology.

[41]  A. Tarkowski,et al.  Histopathological and serological progression of experimental Staphylococcus aureus arthritis , 1992, Infection and immunity.

[42]  A. Weisz,et al.  Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. , 1990, Nucleic acids research.

[43]  R. Holmdahl,et al.  Estrogen induced suppression of collagen arthritis. V: Physiological level of estrogen in DBA/1 mice is therapeutic on established arthritis, suppresses anti-type II collagen T-cell dependent immunity and stimulates polyclonal B-cell activity. , 1990, Journal of autoimmunity.

[44]  R. Holmdahl,et al.  Oestrogen induced suppression of collagen arthritis. IV: Progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. , 1989, Journal of reproductive immunology.

[45]  L. Aarden,et al.  Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.

[46]  R. Holmdahl,et al.  Oestrogen‐Induced Suppression of Collagen Arthritis , 1987 .

[47]  R. Holmdahl,et al.  Female sex hormones suppress development of collagen-induced arthritis in mice. , 1986, Arthritis and rheumatism.

[48]  L. Klareskog,et al.  Homologous type II collagen induces chronic and progressive arthritis in mice. , 1986, Arthritis and rheumatism.